Monotherapy or One-Two Punch Against EGFR-Mutant NSCLC?
Standard of care for patients with EGRF+ lung cancer is treatment with an EGRF targeted drug, but should this be monotherapy, or should it be combined with chemotherapy and/or other drugs?
Medscape Medical News
source https://www.medscape.com/viewarticle/967443?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/967443?src=rss
Comments
Post a Comment